Cyberkinetics gets funds for thought interpreter technology
This article was originally published in Clinica
Neurotechnology firm Cyberkinetics has closed an initial funding round of $5m to advance the development of a brain implant that could allow paralysed patients to work on a computer or control robotic devices by thought alone.
You may also be interested in...
GNC hires Josh Burris as chief US officer; Clasado BioSciences adds Bellchambers as commercial director; and Barentz plans expansion with Cinven investment.
The House passage of a Democratic bill authorizing the federal government to negotiate drug prices in Medicare has sharpened the debate over how prices feed innovation, but the underlying policy stands little chance of being enacted without a Democratic wave in the next election. Pink Sheet's table highlights the key provisions of HR 3 and other pending pricing legislation.